Loading…
Reported covered position: Senior Advisor, Dept. of Health and Human Services; Professional Staff/Sr. Legislative Assistant, House Ways and Means Subcommittee
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: ASTELLAS PHARMA US, INC. · Firm: TODD STRATEGY GROUP
Women's health and menopause. Issues related to P.L.119-21 (H.R. 1): One Big Beautiful Bill Act. Eye screening and access.
Lung Cancer Screening and Prevention Act of 2025
Client: DELFI DIAGNOSTICS · Firm: TODD STRATEGY GROUP
Education around innovative testing for early detection of lung cancer and draft legislation to provide Medicare coverage of certain tests. H.R.1406: Lung Cancer Screening and Prevention Act of 2025.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
PERSONALIS, INC. via TODD STRATEGY GROUP
2026 · third_quarter · Q3
General education about Personalis. Lab test regulatory and reimbursement reform.
Medicare coverage and reimbursement for diagnostics.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MRO CORPORATION via
Source: Senate LDA
| AMERICAN COLLEGE OF RADIOLOGY |
| 18 |
| 2022–2026 |
| MED CLAIMS COMPLIANCE CORPORATION | 18 | 2021–2025 |
| HOSPICE COMPASSUS | 17 | 2021–2025 |
| MERCK & CO., INC. | 17 | 2022–2026 |
| AMERICAN MEDICAL ASSOCIATION | 16 | 2023–2026 |
| TAKEDA PHARMACEUTICALS AMERICA INC | 16 | 2023–2026 |
| ALKERMES, INC. | 15 | 2023–2026 |
| AMGEN, INC. | 15 | 2021–2024 |
| FOX CORPORATION | 15 | 2023–2026 |
| GENMAB | 15 | 2023–2026 |
| APOLLO GLOBAL MANAGEMENT | 14 | 2023–2026 |
| Alnylam Pharmaceuticals, Inc. | 14 | 2021–2024 |
| EMD SERONO, INC. | 14 | 2021–2024 |
| GENENTECH INC | 14 | 2021–2024 |
| ILLUMINA, INC. | 14 | 2023–2026 |
| ALEXION PHARMACEUTICALS, INC. | 13 | 2022–2024 |
| ELI LILLY AND COMPANY | 13 | 2023–2026 |
| SOUTHWEST TRANSPLANT ALLIANCE | 13 | 2023–2026 |
| THE COALITION FOR 21ST CENTURY MEDICINE | 13 | 2021–2024 |
| CAREDX, INC. | 12 | 2021–2026 |
| JOHNSON & JOHNSON SERVICES, INC. | 12 | 2023–2026 |
| NOVO NORDISK, INC. | 12 | 2023–2026 |
| ADULT VACCINE ACCESS COALITION | 11 | 2022–2024 |
| ALLIANCE FOR CELL THERAPY NOW | 11 | 2021–2023 |
| AMERICAN POLICY VENTURES ACTION | 11 | 2024–2026 |
| AMERICAN SOCIETY OF NEPHROLOGY | 11 | 2024–2026 |
| GRAIL, Inc. | 11 | 2021–2024 |
| MUTUAL OF OMAHA | 11 | 2024–2026 |
| OTSUKA AMERICA PHARMACEUTICAL, INC. | 11 | 2023–2026 |
| PFIZER, INC. | 11 | 2023–2026 |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 11 | 2022–2024 |
| THE ORTHOFORUM | 11 | 2023–2026 |
| BIODESIX INC | 10 | 2022–2024 |
| MCKESSON CORPORATION | 10 | 2022–2024 |
| NETLIST, INC. | 10 | 2023–2025 |
| PMI US CORPORATE SERVICES INC. | 10 | 2023–2024 |
| PUERTO RICO FINANCIAL AND FISCAL AUTHORITY | 10 | 2021–2023 |
| U.S. CHAMBER OF COMMERCE GLOBAL INNOVATION POLICY CENTER | 10 | 2024–2026 |
| ASTELLAS PHARMA US, INC. | 9 | 2024–2026 |
| KALDEROS, INC. | 9 | 2024–2026 |
| KARIUS, INC. | 9 | 2022–2024 |
| BIOGEN, INC. | 8 | 2023–2026 |
| COMPASS PATHWAYS INC. | 8 | 2025–2026 |
| GLAXOSMITHKLINE LLC | 8 | 2025–2026 |
| HEALTH SUPPLY US LLC | 8 | 2023–2024 |
| SYNTHETIC BIOLOGY COALITION | 8 | 2021–2022 |
| VANTIVE US HEALTHCARE LLC | 8 | 2025–2026 |
| DELFI DIAGNOSTICS | 7 | 2025–2026 |
| GUARDANT HEALTH, INC. | 7 | 2025–2026 |
| INSULET CORPORATION | 7 | 2025–2026 |
| OSRX PHARMACEUTICALS | 7 | 2023–2025 |
| TRUIST FINANCIAL CORPORATION | 7 | 2023–2024 |
| AVS BIO | 6 | 2024 |
| CORMEDIX, INC. | 6 | 2023–2024 |
| HORIZON THERAPEUTICS USA, INC. | 6 | 2023 |
| NCTA - THE INTERNET & TELEVISION ASSOCIATION | 6 | 2025–2026 |
| NOMI HEALTH, INC. | 6 | 2024–2025 |
| ALLIANCE FOR AMERICA'S PROMISE, INC. | 5 | 2025 |
| CALYXO, INC. | 5 | 2025–2026 |
| FLOW THERAPY | 5 | 2022 |
| GENEOSCOPY, INC. | 5 | 2025–2026 |
| ORGANIZE.ORG | 5 | 2021–2022 |
| VIAL HEALTH TECHNOLOGY INC. | 5 | 2025 |
| BIOTECHNOLOGY INNOVATION ORGANIZATION | 4 | 2023–2024 |
| Cepheid | 4 | 2023–2024 |
| EXELIXIS, INC. | 4 | 2023–2024 |
| FERRING PHARMACEUTICALS, INC. | 4 | 2023–2024 |
| FLEXCARE | 4 | 2024–2025 |
| GILEAD SCIENCES, INC. | 4 | 2023–2024 |
| GINKGO BIOSECURITY | 4 | 2023–2024 |
| GRAND RIVER ASEPTIC MANUFACTURING | 4 | 2021 |
| LYNCH REGENERATIVE MEDICINE, LLC | 4 | 2025 |
| MEDICAL COUNTERMEASURES COALITION | 4 | 2024 |
| VARIAN MEDICAL SYSTEMS, INC. | 4 | 2021 |
| BRIDGEBIO PHARMA | 3 | 2025 |
| BRISTOL-MYERS SQUIBB COMPANY | 3 | 2023–2024 |
| SUNBOUND HOMES | 3 | 2026 |
| VAXESS TECHNOLOGIES, INC | 3 | 2023–2024 |
| VIFOR PHARMA INC | 3 | 2021–2022 |
| DH DIAGNOSTICS, LLC | 2 | 2024 |
| EMERGENT BIOSOLUTIONS INC. | 2 | 2023 |
| FREENOME | 2 | 2026 |
| HEALTHCARE PRIVACY FORUM, LLC D/B/A HEALTHCARE TRUST INSTITUTE | 2 | 2026 |
| INOVIO PHARMACEUTICALS | 2 | 2026 |
| KALEO | 2 | 2026 |
| MRO CORPORATION | 2 | 2026 |
| PERSONALIS, INC. | 2 | 2026 |
| UCB, INC. | 2 | 2023 |
| EMD MILLIPORE | 1 | 2023 |
Lung Cancer Screening and Prevention Act of 2025
Client: DELFI DIAGNOSTICS · Firm: TODD STRATEGY GROUP
Education around innovative testing for early detection of lung cancer and draft legislation to provide Medicare coverage of certain tests. H.R.1406: Lung Cancer Screening and Prevention Act of 2025.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: NOVARTIS, INC. · Firm: TODD STRATEGY GROUP
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832/H.R.1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: NOVARTIS, INC. · Firm: TODD STRATEGY GROUP
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832/H.R.1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025.
Maintaining Investments in New Innovation Act
Client: NOVARTIS, INC. · Firm: TODD STRATEGY GROUP
Medicare Part B. GENErating cost Reductions for U.S. Medicaid (GENEROUS) model. Global Benchmark for Efficient Drug Pricing (GLOBE) Proposed Rule. Guarding U.S. Medicare Against Rising Drugs Costs (GUARD) Proposed Rule. Inflation Reduction Act of 2022 (P.L. 117-169) implementation policy issues. H.R.1672: Maintaining Investments in New Innovation Act or the MINI Act of 2025. Part D redesign and policy issues including non-interference and rebates policy issues. Part B policy issues. Drug cost and pricing policy issues. Medicare rebate policy issues. CMS IPAY Guidance on the Medicare Drug Price Negotiation Program. Medicaid rebate policy issues.
Maintaining Investments in New Innovation Act
Client: NOVARTIS, INC. · Firm: TODD STRATEGY GROUP
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832/H.R.1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025.
Maintaining Investments in New Innovation Act
Client: NOVARTIS, INC. · Firm: TODD STRATEGY GROUP
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832/H.R.1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025.
Issues related to FDA regulation of pharmaceuticals. Drug pricing and Medicare, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041; Affordable Prescriptions for Patients Act. Vaccine Policy, Coverage and Access and the Vaccine Injury Compensation Fund. H.R.2214 - DRUG Act.
Issues related to FDA regulation of pharmaceuticals. Drug pricing and Medicare, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041; Affordable Prescriptions for Patients Act. Vaccine Policy, Coverage and Access and the Vaccine Injury Compensation Fund. H.R.2214 - DRUG Act.
Protecting Patient Access to Cancer and Complex Therapies Act
Client: TAKEDA PHARMACEUTICALS AMERICA, INC. · Firm: TODD STRATEGY GROUP
Rare Disease Issues. H.R.4299: Protecting Patient Access to Cancer and Complex Therapies Act.
Protecting Patient Access to Cancer and Complex Therapies Act
Client: TAKEDA PHARMACEUTICALS AMERICA, INC. · Firm: TODD STRATEGY GROUP
Rare Disease Issues. H.R.4299: Protecting Patient Access to Cancer and Complex Therapies Act.
Protecting Patient Access to Cancer and Complex Therapies Act
Client: TAKEDA PHARMACEUTICALS AMERICA, INC. · Firm: TODD STRATEGY GROUP
Rare Disease Issues. H.R.4299: Protecting Patient Access to Cancer and Complex Therapies Act.
Copyright and content carriage issues. Retransmission consent. H.R.4312: SCORE Act. Online privacy. Spectrum-related issues. Media ownership issues. Streaming issues. Advertising issues. Antitrust enforcement and reform. Corporate tax issues. Private lending regulations.
Copyright and content carriage issues. Retransmission consent. H.R.4312: SCORE Act. Online privacy. Spectrum-related issues. Media ownership issues. Streaming issues. Advertising issues. Antitrust enforcement and reform. Corporate tax issues.
Consolidated Appropriations Act, 2026
Client: AMERICAN MEDICAL ASSOCIATION · Firm: TODD STRATEGY GROUP
NIH Strategic Plan. HIPAA Proposed Rule. Maternal health. Health care consolidation. ICD-11 implementation and other coding issues. Public Law 119-21: One Big Beautiful Bill Act. U.S. Preventive Services Task Force (USPSTF). AMA Physician Practice benchmark survey results. Vaccines and ACIP. Telehealth policy initiatives. H.R.7148: Consolidated Appropriations Act. Long-Term Care Rate Changes.
Direct to Consumer Advertising. 340B Drug Discount Program - Program Implementation & Oversight. Accelerated Approval. Breast Cancer Research. Supply Chain Integrity and Traceability. PBM Reform. Coverage of Accelerated Approval Products. Drug Benefit Design. Orphan Drug Issues. S. 1682/H.R.946: ORPHAN Cures Act. Reimbursement and Coverage of Innovative Products. Lower Costs, More Transparency Act. Lower Costs, More Cures Act. Patient Cost-Sharing. Step Therapy. Value-based Contracting and Communications. User fee policy issues. Pharmacy Benefit Manager reform and policy issues. Drug cost and pricing policy issues. Drug importation policy issues. Competition policy issues. Drug shortages policy issues. IRA price negotiation expansion policy issues. Rare Pediatric Disease Priority Review Voucher program policies. SUSTAIN RFI/discussion draft. Most Favored Nation (MFN) policy. Executive Order: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients. Utilization management policies.
Issues related to FDA regulation of pharmaceuticals. Drug pricing and Medicare, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041; Affordable Prescriptions for Patients Act. Vaccine Policy, Coverage and Access and the Vaccine Injury Compensation Fund. H.R.2214 - DRUG Act.
Issues related to FDA regulation of pharmaceuticals. Drug pricing and Medicare, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041; Affordable Prescriptions for Patients Act. Vaccine Policy, Coverage and Access and the Vaccine Injury Compensation Fund. H.R.2214 - DRUG Act.
Issues related to FDA regulation of pharmaceuticals. Drug pricing and Medicare, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041; Affordable Prescriptions for Patients Act. Vaccine Policy, Coverage and Access and the Vaccine Injury Compensation Fund. H.R.2214 - DRUG Act.
Issues related to FDA regulation of pharmaceuticals. Drug pricing and Medicare, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041; Affordable Prescriptions for Patients Act. Vaccine Policy, Coverage and Access and the Vaccine Injury Compensation Fund. H.R.2214 - DRUG Act.
Direct to Consumer Advertising. 340B Drug Discount Program - Program Implementation & Oversight. Accelerated Approval. Breast Cancer Research. Supply Chain Integrity and Traceability. PBM Reform. Coverage of Accelerated Approval Products. Drug Benefit Design. Orphan Drug Issues. S. 1682/H.R.946: ORPHAN Cures Act. Reimbursement and Coverage of Innovative Products. Lower Costs, More Transparency Act. Lower Costs, More Cures Act. Patient Cost-Sharing. Step Therapy. Value-based Contracting and Communications. User fee policy issues. Pharmacy Benefit Manager reform and policy issues. Drug cost and pricing policy issues. Drug importation policy issues. Competition policy issues. Drug shortages policy issues. IRA price negotiation expansion policy issues. Rare Pediatric Disease Priority Review Voucher program policies. SUSTAIN RFI/discussion draft. Most Favored Nation (MFN) policy. Executive Order: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients. Utilization management policies.
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832/H.R.1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025.
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832/H.R.1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025.
S.864: HELP Copays Act. IRA Implementation. 340B. Heart Recovery Awareness Day. Obesity treatments. MFN. CMS Outpatient Prospective Payment System rule. Peripheral artery disease (PAD). PBM and Insurer Reforms. Stroke care.
Pharmacy Benefit Managers. 340B. Tort Litigation reform. Health care supply chain. S.864: HELP Copays Act. Inflation Reduction Act Implementation.
Pharmacy Benefit Managers. 340B. Tort Litigation reform. Health care supply chain. S.864: HELP Copays Act. Inflation Reduction Act Implementation.
Drug Pricing. S.864: HELP Copays Act.
Drug Pricing. S.864: HELP Copays Act.
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832/H.R.1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025.
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832/H.R.1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025.
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832/H.R.1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025.
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832/H.R.1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025.
Supply Chain. 340B Issues. Genetically Targeted Therapies. PBM policy issues. H.R.5376 - Inflation Reduction Act of 2022 implementation. Most Favored Nation (MFN) policy.
Supply Chain. 340B Issues. Outcomes based contracting/value-based arrangements. Genetically Targeted Therapies. PBM policy issues. H.R.5376 - Inflation Reduction Act of 2022 implementation. Most Favored Nation (MFN) policy.
Medicare coverage of molecular testing for solid organ allograft rejection. Medicare payment of clinical laboratory tests. Implementation of Sec 216 of the Protecting Access to Medicare Act of 2014 (PL 113-93) and RESULTS Act (H.R.5269). Prior authorization of molecular tests.
Medicare coverage of molecular testing for solid organ allograft rejection. Medicare payment of clinical laboratory tests. Implementation of Sec 216 of the Protecting Access to Medicare Act of 2014 (PL 113-93) and RESULTS Act (H.R.5269). Prior authorization of molecular tests.
Medicare coverage of molecular testing for solid organ allograft rejection. Medicare payment of clinical laboratory tests. Implementation of Sec 216 of the Protecting Access to Medicare Act of 2014 (PL 113-93) and RESULTS Act (H.R.5269). Prior authorization of molecular tests.
Lung Cancer Screening and Prevention Act of 2025
Client: DELFI DIAGNOSTICS · Firm: TODD STRATEGY GROUP
Education around innovative testing for early detection of lung cancer and draft legislation to provide Medicare coverage of certain tests. H.R.1406 - Lung Cancer Screening and Prevention Act of 2025.
Lung Cancer Screening and Prevention Act of 2025
Client: DELFI DIAGNOSTICS · Firm: TODD STRATEGY GROUP
Education around innovative testing for early detection of lung cancer and draft legislation to provide Medicare coverage of certain tests. H.R.1406 - Lung Cancer Screening and Prevention Act of 2025.
Lung Cancer Screening and Prevention Act of 2025
Client: DELFI DIAGNOSTICS · Firm: TODD STRATEGY GROUP
Education around innovative testing for early detection of lung cancer and draft legislation to provide Medicare coverage of certain tests. H.R.1406 - Lung Cancer Screening and Prevention Act of 2025.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: PFIZER INC. · Firm: TODD STRATEGY GROUP
Issues related to FDA regulation of pharmaceuticals. H.R.1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Vaccine Policy, Coverage and Access and the Vaccine Injury Compensation Fund. H.R.2214 - DRUG Act. S.832 - EPIC Act of 2025.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: PFIZER INC. · Firm: TODD STRATEGY GROUP
Issues related to FDA regulation of pharmaceuticals. H.R.1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Vaccine Policy, Coverage and Access and the Vaccine Injury Compensation Fund. H.R.2214 - DRUG Act. S.832 - EPIC Act of 2025.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: NOVARTIS, INC. · Firm: TODD STRATEGY GROUP
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832/H.R.1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: NOVARTIS, INC. · Firm: TODD STRATEGY GROUP
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832/H.R.1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025.
Patents. Support for PREVAIL Act. Support for H.R.1574 - RESTORE Patent Rights Act of 2025.
Patents. Support for PREVAIL Act. Support for H.R.1574 - RESTORE Patent Rights Act of 2025.
Maintaining Investments in New Innovation Act
Client: NOVARTIS, INC. · Firm: TODD STRATEGY GROUP
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832/H.R.1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025.
Maintaining Investments in New Innovation Act
Client: NOVARTIS, INC. · Firm: TODD STRATEGY GROUP
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832/H.R.1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025.
Maintaining Investments in New Innovation Act
Client: NOVARTIS, INC. · Firm: TODD STRATEGY GROUP
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832 - EPIC Act of 2025.
Issues related to FDA regulation of pharmaceuticals. Drug pricing and Medicare, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041; Affordable Prescriptions for Patients Act. Vaccine Policy, Coverage and Access and the Vaccine Injury Compensation Fund. H.R.2214 - DRUG Act.
Issues related to FDA regulation of pharmaceuticals. H.R.1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Vaccine Policy, Coverage and Access and the Vaccine Injury Compensation Fund. H.R.2214 - DRUG Act. S.832 - EPIC Act of 2025.
Issues related to FDA regulation of pharmaceuticals. H.R.1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Vaccine Policy, Coverage and Access and the Vaccine Injury Compensation Fund. H.R.2214 - DRUG Act. S.832 - EPIC Act of 2025.
Issues related to FDA regulation of pharmaceuticals. Drug pricing and Medicare, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041; Affordable Prescriptions for Patients Act. Vaccine Policy, Coverage and Access and the Vaccine Injury Compensation Fund. H.R.2214 - DRUG Act.
Issues related to FDA regulation of pharmaceuticals. Drug pricing and Medicare, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041; Affordable Prescriptions for Patients Act. Vaccine Policy, Coverage and Access and the Vaccine Injury Compensation Fund. H.R.2214 - DRUG Act.
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832/H.R.1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025.
Issues related to FDA regulation of pharmaceuticals. H.R.1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Vaccine Policy, Coverage and Access and the Vaccine Injury Compensation Fund. H.R.2214 - DRUG Act. S.832 - EPIC Act of 2025.
Issues related to FDA regulation of pharmaceuticals. H.R.1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Vaccine Policy, Coverage and Access and the Vaccine Injury Compensation Fund. H.R.2214 - DRUG Act. S.832 - EPIC Act of 2025.
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832/H.R.1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025.
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832 - EPIC Act of 2025.
Pharmacy Benefit Managers. 340B. Tort Litigation reform. Health care supply chain. S.864 - HELP Copays Act. Inflation Reduction Act Implementation.
Drug Pricing. S.864 - HELP Copays Act.
Drug Pricing. S.864 - HELP Copays Act.
Drug Pricing. S.864 - HELP Copays Act.
Pharmacy Benefit Managers. 340B. Tort Litigation reform. Health care supply chain. S.864 - HELP Copays Act. Inflation Reduction Act Implementation.
Pharmacy Benefit Managers. 340B. Tort Litigation reform. Health care supply chain. S.864 - HELP Copays Act. Inflation Reduction Act Implementation.
Pharmacy Benefit Managers. 340B. Tort Litigation reform. Health care supply chain. S.864 - HELP Copays Act. Inflation Reduction Act Implementation.
Drug Pricing. S.864 - HELP Copays Act.
Consumer-directed health care and transparency. H.R.5378 - Lower Costs, More Transparency Act.
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832 - EPIC Act of 2025.
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832/H.R.1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025.
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832/H.R.1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025.
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832 - EPIC Act of 2025.
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832/H.R.1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025.
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832/H.R.1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025.
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act.
Supply Chain. 340B Issues. Outcomes based contracting/value-based arrangements. Genetically Targeted Therapies. PBM policy issues. H.R.5376 - Inflation Reduction Act of 2022 implementation.
Supply Chain. 340B Issues. Outcomes based contracting/value-based arrangements. Genetically Targeted Therapies. PBM policy issues. H.R.5376 - Inflation Reduction Act of 2022 implementation. Most Favored Nation (MFN) policy.
Supply Chain. 340B Issues. Outcomes based contracting/value-based arrangements. Genetically Targeted Therapies. PBM policy issues. H.R.5376 - Inflation Reduction Act of 2022 implementation.
Supply Chain. 340B Issues. Outcomes based contracting/value-based arrangements. Genetically Targeted Therapies. PBM policy issues. H.R.5376 - Inflation Reduction Act of 2022 implementation. Most Favored Nation (MFN) policy.
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act.
Medicare coverage of molecular testing for solid organ allograft rejection. Medicare payment of clinical laboratory tests. Implementation of Sec 216 of the Protecting Access to Medicare Act of 2014 (PL 113-93) and RESULTS Act (H.R.5269). Prior authorization of molecular tests.
Medicare coverage of molecular testing for solid organ allograft rejection. Medicare payment of clinical laboratory tests. Implementation of Sec 216 of the Protecting Access to Medicare Act of 2014 (PL 113-93) and RESULTS Act (H.R.5269). Prior authorization of molecular tests.
Medicare coverage of molecular testing for solid organ allograft rejection. Medicare payment of clinical laboratory tests. Implementation of Sec 216 of the Protecting Access to Medicare Act of 2014 (PL 113-93) and RESULTS Act (H.R.5269). Prior authorization of molecular tests.
Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
Client: GRAIL, INC. · Firm: TODD STRATEGY GROUP
Issues related to oncology and multi cancer early detection, including diagnostics and screening. H.R.2407 - Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act.
Labor, HHS and Education appropriations bill. H.R.3561 Monitored issues related to consumer directed health care and transparency. Issues related to surprise medical billing. Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023. H.R. 4507 ACA Exchanges.
Appropriations. Monitored issues related to consumer directed health care and transparency. Issues related to surprise medical billing. Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023. H.R.4507 - Transparency in Coverage Act of 2023.
Labor, HHS and Education appropriations bill. H.R.3561 Monitored issues related to consumer directed health care and transparency. Issues related to surprise medical billing. Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023. H.R. 4507 ACA Exchanges.
Appropriations. Monitored issues related to consumer directed health care and transparency. Issues related to surprise medical billing. Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023. H.R.4507 - Transparency in Coverage Act of 2023.
Consumer-directed health care and transparency. H.R.5378 - Lower Costs, More Transparency Act.
Consumer-directed health care and transparency. H.R.5378 - Lower Costs, More Transparency Act.
Medicare and Medicaid Issues H.R.5547/S.476 - Maintaining Investments in New Innovation (MINI) Act. H.R.5539/S.3131 - ORPHAN Cures Act. Home Infusion.
General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection. H.R.5547/S.476 - Maintaining Investments in New Innovation (MINI) Act. H.R.5539/S.3131 - ORPHAN Cures Act.
General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection. H.R.5547/S.476 - Maintaining Investments in New Innovation (MINI) Act. H.R.5539/S.3131 - ORPHAN Cures Act.
Medicare and Medicaid Issues H.R.5547/S.476 - Maintaining Investments in New Innovation (MINI) Act. H.R.5539/S.3131 - ORPHAN Cures Act. Home Infusion.
Maintaining Investments in New Innovation Act
Client: ALEXION PHARMACEUTICALS, INC. · Firm: TODD STRATEGY GROUP
General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection. H.R.5547/S.476 - Maintaining Investments in New Innovation (MINI) Act. H.R.5539/S.3131 - ORPHAN Cures Act.
Maintaining Investments in New Innovation Act
Client: ALNYLAM PHARMACEUTICALS, INC. · Firm: TODD STRATEGY GROUP
Medicare and Medicaid Issues H.R.5547/S.476 - Maintaining Investments in New Innovation (MINI) Act. H.R.5539/S.3131 - ORPHAN Cures Act. Home Infusion.
Maintaining Investments in New Innovation Act
Client: ALEXION PHARMACEUTICALS, INC. · Firm: TODD STRATEGY GROUP
General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection. H.R.5547/S.476 - Maintaining Investments in New Innovation (MINI) Act. H.R.5539/S.3131 - ORPHAN Cures Act.
Maintaining Investments in New Innovation Act
Client: ALNYLAM PHARMACEUTICALS, INC. · Firm: TODD STRATEGY GROUP
Medicare and Medicaid Issues H.R.5547/S.476 - Maintaining Investments in New Innovation (MINI) Act. H.R.5539/S.3131 - ORPHAN Cures Act. Home Infusion.
Advancing Menopause Care and Mid-Life Women’s Health Act
Client: ASTELLAS PHARMA US, INC. · Firm: TODD STRATEGY GROUP
Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues. PSA Screening for HIM Act; H.R. 8223/S. 4246 Advancing Menopause and Mid-Life Womens Health Act. Pharmacy Benefit Manager reform. Issues related to March-In.
2026 · third_quarter · Q3
HIPAA Coordinated Care Rulemaking.
Filing targets: Health & Human Services, Dept of (HHS)
INOVIO PHARMACEUTICALS via TODD STRATEGY GROUP
2026 · third_quarter · Q3
General issues related to rare disease and orphan drugs.
HEALTHCARE PRIVACY FORUM, LLC D/B/A HEALTHCARE TRUST INSTITUTE via TODD STRATEGY GROUP
2026 · third_quarter · Q3
Issues related to healthcare data privacy, cybersecurity, and artificial intelligence.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
FREENOME via TODD STRATEGY GROUP
2026 · third_quarter · Q3
Medicare coverage and reimbursement for diagnostics.
General education about Freenome.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PERSONALIS, INC. via TODD STRATEGY GROUP
2026 · third_quarter · RR
General education about Personalis. Lab test regulatory and reimbursement reform. Medicare coverage and reimbursement for diagnostics.
General education about Personalis. Lab test regulatory and reimbursement reform. Medicare coverage and reimbursement for diagnostics.
FREENOME via TODD STRATEGY GROUP
2026 · third_quarter · RR
General education about Freenome. Medicare coverage and reimbursement for diagnostics.
General education about Freenome. Medicare coverage and reimbursement for diagnostics.
MRO CORPORATION via TODD STRATEGY GROUP
2026 · third_quarter · RR
HIPAA Coordinated Care Rulemaking.
INOVIO PHARMACEUTICALS via TODD STRATEGY GROUP
2026 · third_quarter · RR
General issues related to rare disease and orphan drugs.
HEALTHCARE PRIVACY FORUM, LLC D/B/A HEALTHCARE TRUST INSTITUTE via TODD STRATEGY GROUP
2026 · third_quarter · RR
Issues related to healthcare data privacy, cybersecurity, and artificial intelligence.
GUARDANT HEALTH, INC. via TODD STRATEGY GROUP
2026 · second_quarter · 2T
Cancer screening access. Precision diagnostics, cancer care and preventive screening innovation.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
U.S. CHAMBER OF COMMERCE GLOBAL INNOVATION POLICY CENTER via TODD STRATEGY GROUP
2026 · third_quarter · Q3
Copyright issues. Intellectual property protection.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OTSUKA AMERICA PHARMACEUTICAL, INC. via TODD STRATEGY GROUP
2026 · third_quarter · Q3
Drug Pricing Policy. Issues relating to mental health as a chronic condition. Agitation in Alzheimer's.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELI LILLY AND COMPANY via TODD STRATEGY GROUP
2026 · third_quarter · Q3
Health insurance accessibility. Artificial Intelligence in health care.
Medicare & Medicaid prescription drug diagnosis and screening reimbursement pricing, coverage, value and access. CMS National Coverage Determination on Alzheimer's disease. Implementation of the Inflation Reduction Act.
Drug pricing, coverage, value, access and quality. Prescription drug approval. Drug importation. 340 B. Intellectual property. Pharmaceutical supply chain issues and shortages. Transparency. Issues related to intellectual property protection and market access within current trade negotiations.
ASTELLAS PHARMA US, INC. via TODD STRATEGY GROUP
2026 · third_quarter · Q3
IP and Bayh-Dole Act.
Implementation of the Inflation Reduction Act. PSA screening bills. Health care transparency.
Medicare Part D.
AMERICAN MEDICAL ASSOCIATION via TODD STRATEGY GROUP
2026 · third_quarter · Q3
NIH Strategic Plan. HIPAA Proposed Rule. Maternal health. Health care consolidation. ICD-11 implementation and other coding issues. Public Law 119-21: One Big Beautiful Bill Act. U.S. Preventive Services Task Force (USPSTF). AMA Physician Practice benchmark survey results. Vaccines and ACIP. Telehealth policy initiatives. H.R.7148: Consolidated Appropriations Act. Long-Term Care Rate Changes.
Drug shortages.
Alternative payment model bonuses and incentive payments and freezing the qualifying provider revenue thresholds. Interoperability and Prior Authorization Final Rule. Hospital Inpatient Prospective Payment Systems. CMMI Reforms. Medicare Access and CHIP Reauthorization Act (MACRA). Accountable Care Organizations (ACOs) and Alternative Payment Models (APMs) in Medicare. Indirect practice expense. Medicare physician payment issues. MIPS quality and cost measures.
PUERTO RICO DEPARTMENT OF HEALTH via TODD STRATEGY GROUP
2026 · third_quarter · Q3
Appropriations.
Medicare Coverage and Reimbursement. Medicaid Funding.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
MYRIAD GENETICS, INC. via TODD STRATEGY GROUP
2026 · third_quarter · Q3
Prior Authorization for Medicare Advantage.
Filing targets: HOUSE OF REPRESENTATIVES
GLAXOSMITHKLINE LLC via TODD STRATEGY GROUP
2026 · third_quarter · Q3
Government funding. Medicare & Drug Pricing. Medicaid, 340B and Reimbursement.
PBM reform. FDA & Biopharma issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GENMAB via TODD STRATEGY GROUP
2026 · third_quarter · Q3
General Medicare/Medicaid Issues. 340B Issues.
Prescription Drug Pricing. Implementation of Inflation Reduction Act of 2022.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FOX CORPORATION via TODD STRATEGY GROUP
2026 · third_quarter · Q3
Copyright and content carriage issues. Retransmission consent. Online privacy. Spectrum-related issues. Media ownership issues. Streaming issues. Advertising issues. Antitrust enforcement and reform. Corporate tax issues. College sports media rights. First Amendment issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CAREDX, INC. via TODD STRATEGY GROUP
2026 · second_quarter · 2T
Medicare coverage of molecular testing for solid organ allograft rejection. Medicare payment of clinical laboratory tests. Implementation of Sec 216 of the Protecting Access to Medicare Act of 2014 (PL 113-93) and RESULTS Act (H.R.5269). Prior authorization of molecular tests.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
NOVO NORDISK INC. via TODD STRATEGY GROUP
2026 · third_quarter · Q3
Implementation of Inflation Reduction Act. Health care supply chain. Treat and Reduce Obesity Act.
Pharmacy Benefit Manager Reform. 340B.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
DELFI DIAGNOSTICS via TODD STRATEGY GROUP
2026 · third_quarter · Q3
Issues related to intellectual property protection and market access. Drug pricing, coverage, value, access and quality. IRA Implementation. Transparency issues.
US Tariffs patient protection. Supply chain issues and shortages.
Education around innovative testing for early detection of lung cancer and draft legislation to provide Medicare coverage of certain tests. Health insurance accessibility.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SOUTHWEST TRANSPLANT ALLIANCE via TODD STRATEGY GROUP
2026 · third_quarter · Q3
Organ procurement regulations. Increasing access to organ transplant.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
COMPASS PATHWAYS INC. via TODD STRATEGY GROUP
2026 · third_quarter · Q3
General education on Compass Pathways. Mental health and PTSD. Psychedelic medicines.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
AMERICAN SOCIETY OF NEPHROLOGY via TODD STRATEGY GROUP
2026 · third_quarter · Q3
Kidney transplantation policy. Officer of Kidney Health.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALKERMES, INC. via TODD STRATEGY GROUP
2026 · third_quarter · Q3
Maintaining six protected classes for bipolar disorders and schizophrenia under Medicare Part D.
Prescription drug pricing, including MDRP. Substance Use Disorder Policy. Implementation of Inflation Reduction Act. Patient access.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SUNBOUND HOMES via TODD STRATEGY GROUP
2026 · third_quarter · Q3
General discussions around Medicare and Medicaid. Long term care issues. AI in healthcare. Data privacy and security.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PFIZER INC. via TODD STRATEGY GROUP
2026 · third_quarter · Q3
Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Codification. FDA User Fee Agreements: 2027 PDUFA Cycle. 340B Program Reform. Inflation Reduction Act (IRA). Prior Authorization. Step Therapy Practices. FDA Modernization and Reforms. Drug Pricing. PBM Reform. Vaccine Access and Coverage.
Medicare/Medicaid Issues.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ILLUMINA, INC. via TODD STRATEGY GROUP
2026 · third_quarter · Q3
General issues related to trade.
Discussions related to National Institutes of Health (NIH) funding.
Discussions related to U.S. government disease surveillance programs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOGEN, INC. via TODD STRATEGY GROUP
2026 · third_quarter · Q3
IRA implementation. Issues related to drug pricing. 340B Program. Supply Chain. Issues related to patient affordability and access including copay and coverage reform. Issues related to PBM reform. PDUFA, drug reviews, approval pathways, PPRV Program, clinical trials. Issues related to rare diseases, including the Orphan Drug and ORPHAN CURES Act, rare disease research and screening, and patient access to therapies.
Issues related to Alzheimer's disease and dementia, including screening, diagnosis, and care. Issues related to postpartum depression screening, detection, and education. Issues related to ALS, lupus, and kidney disease policy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VANTIVE US HEALTHCARE LLC via TODD STRATEGY GROUP
2026 · third_quarter · Q3
Kidney and dialysis care. Issues related to ESRD reimbursement.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
TAKEDA PHARMACEUTICALS AMERICA, INC. via TODD STRATEGY GROUP
2026 · third_quarter · Q3
Rare Disease Issues. H.R.4299: Protecting Patient Access to Cancer and Complex Therapies Act.
General Medicare/Medicaid Issues. Implementation of Inflation Reduction Act of 2022.
Issues related to tariff and trade policy.
Filing targets: HOUSE OF REPRESENTATIVES
SIDECAR HEALTH via TODD STRATEGY GROUP
2026 · third_quarter · Q3
Consumer-directed health care and transparency. Issues regarding risk adjustment programs and price transparency. Issues related to the proposed rule, the Notice of Benefit and Payment Parameters.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
NOVARTIS, INC. via TODD STRATEGY GROUP
2026 · third_quarter · Q3
Direct to Consumer Advertising. 340B Drug Discount Program - Program Implementation & Oversight. Accelerated Approval. Breast Cancer Research. Supply Chain Integrity and Traceability. PBM Reform. Coverage of Accelerated Approval Products. Drug Benefit Design. Orphan Drug Issues. S. 1682/H.R.946: ORPHAN Cures Act. Reimbursement and Coverage of Innovative Products. Lower Costs, More Transparency Act. Lower Costs, More Cures Act. Patient Cost-Sharing. Step Therapy. Value-based Contracting and Communications. User fee policy issues. Pharmacy Benefit Manager reform and policy issues. Drug cost and pricing policy issues. Drug importation policy issues. Competition policy issues. Drug shortages policy issues. IRA price negotiation expansion policy issues. Rare Pediatric Disease Priority Review Voucher program policies. SUSTAIN RFI/discussion draft. Most Favored Nation (MFN) policy. Executive Order: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients. Utilization management policies.
Outbound investment issues.
NCTA - THE INTERNET & TELEVISION ASSOCIATION via TODD STRATEGY GROUP
2026 · third_quarter · Q3
College Athletics/Sports Media. Broadband Deployment. BEAD and Rural Broadband funding. Spectrum/wireless policy. Affordability, Lifeline, Consumer protection. Network security/supply chain. Online safety. Video programming.
Filing targets: HOUSE OF REPRESENTATIVES
MUTUAL OF OMAHA via TODD STRATEGY GROUP
2026 · third_quarter · Q3
Medicare Advantage transparency and accountability bills. Bills related to Durable Medical Equipment (DME) reimbursement reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
JOHNSON & JOHNSON SERVICES, INC. via TODD STRATEGY GROUP
2026 · third_quarter · Q3
VA/military affairs.
S.864: HELP Copays Act. IRA Implementation. 340B. Heart Recovery Awareness Day. Obesity treatments. MFN. CMS Outpatient Prospective Payment System rule. Peripheral artery disease (PAD). PBM and Insurer Reforms. Stroke care.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
INSULET CORPORATION via TODD STRATEGY GROUP
2026 · third_quarter · Q3
General education on diabetes care. General education about Insulet.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CALYXO, INC. via TODD STRATEGY GROUP
2026 · third_quarter · Q3
General education on kidney care. General education about Calyxo.
Filing targets: HOUSE OF REPRESENTATIVES
BAYER CORPORATION via TODD STRATEGY GROUP
2026 · third_quarter · Q3
Tax policy.
Tariffs.
CMMI models. IRA implementation.
IP protection.
AMERICAN COLLEGE OF RADIOLOGY via TODD STRATEGY GROUP
2026 · third_quarter · Q3
Medicare Physician Fee Schedule Provider Reimbursement. Medicare and Medicaid Issues. Value of imaging.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
MERCK & CO., INC. via TODD STRATEGY GROUP
2026 · third_quarter · Q3
340B Program. Issues related to drug pricing. General pharmaceutical issues. Pubic health issues. Issues related to MFN. Appropriations and budget legislation for FY27. Reconciliation. Issues related to supply chain and shortages. Issues on vaccine policy. PBM reform. FDA issues. IRA Implementation.
Issues related to Medicare Part B and D. Issues related to Medicaid Drug Rebate Program (MDRP).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
APOLLO GLOBAL MANAGEMENT via TODD STRATEGY GROUP
2026 · third_quarter · Q3
General education on Apollo Global Management. Insurance regulation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VANTIVE US HEALTHCARE LLC via TODD STRATEGY GROUP
2026 · second_quarter · Q2
Kidney and dialysis care.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
TAKEDA PHARMACEUTICALS AMERICA, INC. via TODD STRATEGY GROUP
2026 · second_quarter · Q2
Rare Disease Issues. H.R.4299: Protecting Patient Access to Cancer and Complex Therapies Act.
General Medicare/Medicaid Issues. Implementation of Inflation Reduction Act of 2022.
Issues related to tariff and trade policy.
Filing targets: HOUSE OF REPRESENTATIVES
SUNBOUND HOMES via TODD STRATEGY GROUP
2026 · second_quarter · Q2
General discussions around Medicare and Medicaid. Implementation of CRUSH initiative. Long term care issues.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SOUTHWEST TRANSPLANT ALLIANCE via TODD STRATEGY GROUP
2026 · second_quarter · Q2
Organ procurement regulations. Increasing access to organ transplant.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SIDECAR HEALTH via TODD STRATEGY GROUP
2026 · second_quarter · Q2
Consumer-directed health care and transparency.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PFIZER INC. via TODD STRATEGY GROUP
2026 · second_quarter · Q2
Issues related to tariff and trade policy.
Issues related to tariff and trade policy. International Supply Chain.
Issues related to FDA regulation of pharmaceuticals. Drug pricing and Medicare, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041; Affordable Prescriptions for Patients Act. Vaccine Policy, Coverage and Access and the Vaccine Injury Compensation Fund. H.R.2214 - DRUG Act.
OTSUKA AMERICA PHARMACEUTICAL, INC. via TODD STRATEGY GROUP
2026 · second_quarter · Q2
Drug Pricing Policy. Issues relating to mental health as a chronic condition. Agitation in Alzheimer's.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVO NORDISK INC. via TODD STRATEGY GROUP
2026 · second_quarter · Q2
Implementation of Inflation Reduction Act. Pharmacy Benefit Manager Reform. Health care supply chain. 340B. Treat and Reduce Obesity Act.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
MYRIAD GENETICS, INC. via TODD STRATEGY GROUP
2026 · second_quarter · Q2
Prior Authorization for Medicare Advantage.
Filing targets: HOUSE OF REPRESENTATIVES
MUTUAL OF OMAHA via TODD STRATEGY GROUP
2026 · second_quarter · Q2
Education related to health insurance options.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MERCK & CO., INC. via TODD STRATEGY GROUP
2026 · second_quarter · Q2
Drug Pricing. S.864: HELP Copays Act.
340B issues. Antimicrobial resistance. Supply Chain. Vaccine issues. Food and Drug Administration issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
JOHNSON & JOHNSON SERVICES, INC. via TODD STRATEGY GROUP
2026 · second_quarter · Q2
Pharmacy Benefit Managers. 340B. Tort Litigation reform. Health care supply chain. S.864: HELP Copays Act. Inflation Reduction Act Implementation.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ILLUMINA, INC. via TODD STRATEGY GROUP
2026 · second_quarter · Q2
General discussions related to FDA regulation of diagnostics.
General trade issues.
General discussions related to Medicare reimbursement for diagnostic tests.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GUARDANT HEALTH, INC. via TODD STRATEGY GROUP
2026 · second_quarter · Q2
Cancer screening access. Precision diagnostics, cancer care and preventive screening innovation.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
GLAXOSMITHKLINE LLC via TODD STRATEGY GROUP
2026 · second_quarter · Q2
Drug pricing. Implementation of IRA. Supply chain issues.
Medicare and Medicaid issues. 340B Issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GENMAB via TODD STRATEGY GROUP
2026 · second_quarter · Q2
General Medicare/Medicaid Issues. 340B Issues.
Prescription Drug Pricing. Implementation of Inflation Reduction Act of 2022.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FOX CORPORATION via TODD STRATEGY GROUP
2026 · second_quarter · Q2
Copyright and content carriage issues. Retransmission consent. H.R.4312: SCORE Act. Online privacy. Spectrum-related issues. Media ownership issues. Streaming issues. Advertising issues. Antitrust enforcement and reform. Corporate tax issues. Private lending regulations.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DELFI DIAGNOSTICS via TODD STRATEGY GROUP
2026 · second_quarter · Q2
Education around innovative testing for early detection of lung cancer and draft legislation to provide Medicare coverage of certain tests. H.R.1406: Lung Cancer Screening and Prevention Act of 2025.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COMPASS PATHWAYS INC. via TODD STRATEGY GROUP
2026 · second_quarter · Q2
General education on Compass Pharmaceuticals. Mental health and PTSD.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
CAREDX, INC. via TODD STRATEGY GROUP
2026 · second_quarter · Q2
Medicare coverage of molecular testing for solid organ allograft rejection. Medicare payment of clinical laboratory tests. Implementation of Sec 216 of the Protecting Access to Medicare Act of 2014 (PL 113-93) and RESULTS Act (H.R.5269). Prior authorization of molecular tests.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
BIOGEN, INC. via TODD STRATEGY GROUP
2026 · second_quarter · Q2
Alzheimer's Disease. Medicare Reimbursement for Prescription Drugs. Screening and Diagnosis, PET scan coverage and reimbursement and dementia care. 340B Program. PPRV (Pediatric Priority Review Voucher) program.
Drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements. Implementation of Inflation Reduction Act of 2022. Issues related to maternal health. 340B Program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BAYER CORPORATION via TODD STRATEGY GROUP
2026 · second_quarter · Q2
Drug pricing. Implementation of Inflation Reduction Act of 2022.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC. via TODD STRATEGY GROUP
2026 · second_quarter · Q2
Women's health.
Prescription drug pricing.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
APOLLO GLOBAL MANAGEMENT via TODD STRATEGY GROUP
2026 · second_quarter · Q2
General Education on Apollo Global Management. Insurance regulation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN SOCIETY OF NEPHROLOGY via TODD STRATEGY GROUP
2026 · second_quarter · Q2
Kidney transplantation policy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN MEDICAL ASSOCIATION via TODD STRATEGY GROUP
2026 · second_quarter · Q2
Physician Payment Reform.
Medicare and Medicaid Issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN COLLEGE OF RADIOLOGY via TODD STRATEGY GROUP
2026 · second_quarter · Q2
Medicare Physician Fee Schedule Provider Reimbursement. PAMA AUC. Medicare and Medicaid Issues. Value of imaging.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
ALKERMES, INC. via TODD STRATEGY GROUP
2026 · second_quarter · Q2
Prescription drug pricing, including MDRP. Substance Use Disorder Policy. Implementation of Inflation Reduction Act of 2022. Medicaid drug rebate program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVARTIS, INC. via TODD STRATEGY GROUP
2026 · second_quarter · Q2
Tariffs.
Supply Chain. 340B Issues. Genetically Targeted Therapies. PBM policy issues. H.R.5376 - Inflation Reduction Act of 2022 implementation. Most Favored Nation (MFN) policy.
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832/H.R.1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025.
U.S. CHAMBER OF COMMERCE GLOBAL INNOVATION POLICY CENTER via TODD STRATEGY GROUP
2026 · second_quarter · Q2
Copyright issues. Intellectual property protection.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SUNBOUND HOMES via TODD STRATEGY GROUP
2026 · first_quarter · RR
Waste, fraud, and abuse.
SIEMENS HEALTHINEERS via TODD STRATEGY GROUP
2026 · first_quarter · 1T
General Medicare / Medicaid Issues. Medicare Rulemaking. Medicare reimbursement for radiation oncology. Telehealth.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PUERTO RICO DEPARTMENT OF HEALTH via TODD STRATEGY GROUP
2026 · second_quarter · Q2
Medicare Coverage and Reimbursement. Medicaid Funding.
Appropriations.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
THE ORTHOFORUM via TODD STRATEGY GROUP
2026 · second_quarter · 2T
Physician Reimbursement. Physician-owned hospitals. Medicare and Medicaid Issues. Payment Reform. Price transparency.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
NCTA - THE INTERNET & TELEVISION ASSOCIATION via TODD STRATEGY GROUP
2026 · second_quarter · Q2
Spectrum. General telecommunications issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · 2T
Prescription drug pricing. Medical countermeasure development and procurement.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Health & Human Services, Dept of (HHS)
KALDEROS, INC. via TODD STRATEGY GROUP
2026 · first_quarter · 1T
Government pricing discounts. Claims adjudication.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INSULET CORPORATION via TODD STRATEGY GROUP
2026 · second_quarter · Q2
General education on diabetes care. General education about Insulet.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GENEOSCOPY, INC. via TODD STRATEGY GROUP
2026 · first_quarter · 1T
Colorectal Cancer Screening Access. Medicare Quality Measures. USPSTF colorectal cancer screening guidelines.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELI LILLY AND COMPANY via TODD STRATEGY GROUP
2026 · second_quarter · Q2
Alzheimer's Disease. Anti Obesity Medication.
Medicare/Medicaid Coverage and Reimbursement. PDUFA. 340B Program. Issues related to drug compounding.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CALYXO, INC. via TODD STRATEGY GROUP
2026 · second_quarter · Q2
General education on kidney care. General education about Calyxo.
Filing targets: HOUSE OF REPRESENTATIVES
AMERICAN POLICY VENTURES ACTION via TODD STRATEGY GROUP
2026 · first_quarter · 1T
General education around APVA and its mission to promote American competitiveness, including issues related to tax policy and economic opportunity and growth. Issues relating to family policy and permitting reform.
General education around APVA and its mission to promote American competitiveness, including issues related to tax policy and economic opportunity and growth. Issues relating to family policy and permitting reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VANTIVE US HEALTHCARE LLC via TODD STRATEGY GROUP
2026 · first_quarter · Q1
Kidney and dialysis care.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
U.S. CHAMBER OF COMMERCE GLOBAL INNOVATION POLICY CENTER via TODD STRATEGY GROUP
2026 · first_quarter · Q1
Copyright issues. Intellectual property protection.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TAKEDA PHARMACEUTICALS AMERICA, INC. via TODD STRATEGY GROUP
2026 · first_quarter · Q1
General Medicare/Medicaid Issues. Implementation of Inflation Reduction Act of 2022.
Rare Disease Issues. H.R.4299: Protecting Patient Access to Cancer and Complex Therapies Act.
Filing targets: HOUSE OF REPRESENTATIVES
SOUTHWEST TRANSPLANT ALLIANCE via TODD STRATEGY GROUP
2026 · first_quarter · Q1
Organ procurement regulations. Increasing access to organ transplant.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SIEMENS HEALTHINEERS via TODD STRATEGY GROUP
2026 · first_quarter · Q1
General Medicare / Medicaid Issues. Medicare Rulemaking. Medicare reimbursement for radiation oncology. Telehealth.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SIDECAR HEALTH via TODD STRATEGY GROUP
2026 · first_quarter · Q1
Consumer-directed health care and transparency.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PUERTO RICO DEPARTMENT OF HEALTH via TODD STRATEGY GROUP
2026 · first_quarter · Q1
Appropriations.
Medicare Coverage and Reimbursement. Medicaid Funding.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PFIZER INC. via TODD STRATEGY GROUP
2026 · first_quarter · Q1
Issues related to tariff and trade policy.
Issues related to FDA regulation of pharmaceuticals. Drug pricing and Medicare, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041; Affordable Prescriptions for Patients Act. Vaccine Policy, Coverage and Access and the Vaccine Injury Compensation Fund. H.R.2214 - DRUG Act.
OTSUKA AMERICA PHARMACEUTICAL, INC. via TODD STRATEGY GROUP
2026 · first_quarter · Q1
Drug Pricing Policy. Issues relating to mental health as a chronic condition. Agitation in Alzheimer's.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE ORTHOFORUM via TODD STRATEGY GROUP
2026 · first_quarter · Q1
Physician Reimbursement. Physician-owned hospitals. Medicare and Medicaid Issues. Payment Reform. Price transparency.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
NOVO NORDISK INC. via TODD STRATEGY GROUP
2026 · first_quarter · Q1
Implementation of Inflation Reduction Act. Pharmacy Benefit Manager Reform. Health care supply chain. 340B. Treat and Reduce Obesity Act.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
NOVARTIS, INC. via TODD STRATEGY GROUP
2026 · first_quarter · Q1
Tariffs.
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832/H.R.1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025.
Supply Chain. 340B Issues. Outcomes based contracting/value-based arrangements. Genetically Targeted Therapies. PBM policy issues. H.R.5376 - Inflation Reduction Act of 2022 implementation. Most Favored Nation (MFN) policy.
NCTA - THE INTERNET & TELEVISION ASSOCIATION via TODD STRATEGY GROUP
2026 · first_quarter · Q1
Spectrum. General telecommunications issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Women's health and menopause. Issues related to P.L.119-21 (H.R. 1): One Big Beautiful Bill Act. Eye screening and access.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Medicare Part B. GENErating cost Reductions for U.S. Medicaid (GENEROUS) model. Global Benchmark for Efficient Drug Pricing (GLOBE) Proposed Rule. Guarding U.S. Medicare Against Rising Drugs Costs (GUARD) Proposed Rule. Inflation Reduction Act of 2022 (P.L. 117-169) implementation policy issues. H.R.1672: Maintaining Investments in New Innovation Act or the MINI Act of 2025. Part D redesign and policy issues including non-interference and rebates policy issues. Part B policy issues. Drug cost and pricing policy issues. Medicare rebate policy issues. CMS IPAY Guidance on the Medicare Drug Price Negotiation Program. Medicaid rebate policy issues.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Drug pricing. 340B. PBM reform. Copay assistance. GRAS reform. Small molecule drug innovation. Womens health. Biotech investment.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to tariff and trade policy. International Supply Chain.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE